Effect of Denosumab and Alendronate on osteoporosis in hemodialysis patients :a randomized controlled trial
Not Applicable
- Conditions
- osteoporosis
- Registration Number
- JPRN-UMIN000022985
- Lead Sponsor
- Makita general hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 80
Inclusion Criteria
Not provided
Exclusion Criteria
) Patients who are considered to be contraindicated for denosumab. 2) Patients who are considered to be contraindicated for alendronate. 3) Cancer patients. 4) Patients who have pretreated with bisphosphonate in recent 6 months. 5) Patients who have pretreated with denosumab in recent 6 months. 6) Patients whose corrected Ca is less than 8.4 mg/dL. 7) Patients with severe liver disease 8) Patients with severe heart disease 9) Patients may be pregnant 10) Patients who have bad oral consitions 11) Patients who are thought to be inappropriate for this study by physician.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Percent change of bone mineral density (BMD) in lumber spine, femoral neck and distal radius at 6, 12 month after intervention
- Secondary Outcome Measures
Name Time Method Percent change of bone metabolism markers, rate of continuation, side effect at 6, 12 month after intervention